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  BLOCKERS AND MORTALITY IN COPD
Author’s reply to Wolstenholme and Sanfilippo and
colleagues
Jennifer K Quint clinical lecturer and honorary consultant
Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
The responders have highlighted some important issues that
merit further investigation.1-4
We agree with Wolstenholme that it seems counterintuitive to
use β blockers and β agonists in patients with chronic obstructive
pulmonary disease (COPD), but most patients in our study were
prescribed cardioselective β blockers, so theoretically β blockade
would not negate agonist activity in the lungs. Some studies
have even suggested that β blockers have beneficial effects on
COPD and reduce exacerbations and mortality independent of
cardiovascular risk.5 Although we agree that antimuscarinic
agents are also effective bronchodilators, cautionmay be needed
in this patient group owing to concomitant cardiac arrhythmias.
This is an area in which more research is needed.
As Sanfilippo and colleagues state, primary percutaneous
coronary intervention is an important and increasingly used
treatment for ST-elevation myocardial infarction (STEMI). Our
data (not published) suggested that patients with COPD are less
likely than those without COPD to undergo percutaneous
coronary intervention, and in our study the number of patients
undergoing this intervention was too small to include in the
analysis. We agree that percutaneous coronary intervention is
becoming more common and may be an important factor. We
are currently undertaking a large and more up to date study of
patients with COPD using data from the Myocardial Ischemia
National Audit Project (MINAP) to investigate this and several
other factors.
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